DePinho, Pamela A Silver, Giulio Draetta, Michael G. The company was founded by Joseph Araujo, Ronald A.
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares. Karyopharm has several investigational programs in clinical or preclinical development. RAPT Therapeutics (NASDAQ:RAPT) Shareholders Have Enjoyed A 33 Share Price Gain. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S.
Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Unsurprisingly, earnings also fell seriously short of forecasts, turning into a per-share loss of US0.56. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. (NASDAQ:RAPT) missed earnings with its latest first-quarter results, disappointing overly-optimistic forecasters.It was not a great statutory result, with revenues coming in 85 lower than the analysts predicted.